• Home
  • News Reports
  • Cancer drug co-developed by Duke-NUS Medical School to start patient trials

Cancer drug co-developed by Duke-NUS Medical School to start patient trials

10 March 2017 | Research

Duke-NUS Medical School and A*STAR, co-developers of home-grown blood cancer drug ETC-206, hope to start trials on patients who are in the late stages of the cancer in August 2017. The drug, which is orally administered, will be tested on blood cancer patients in groups of three. Clinical trials began in December 2016 and will test up to 34 healthy volunteers.

  • Home
  • News Reports
  • Cancer drug co-developed by Duke-NUS Medical School to start patient trials